Published on
Last updated on
China Issues GMP Inspection Guidelines for Sterile, Implant, IVD, Denture and Standalone Software Devices

China Issues GMP Inspection Guidelines for Sterile, Implant, IVD, Denture and Standalone Software Devices
On October 28 and 30, 2026, China’s National Medical Products Administration (NMPA) issued five revised Good Manufacturing Practice (GMP) inspection guidelines covering sterile medical devices, implantable devices, in vitro diagnostic reagents, custom-made dentures and standalone medical software.
The guidelines support the revised Good Manufacturing Practice for Medical Devices, which took effect on November 1, 2026. They provide authorities with category-specific inspection items for manufacturing-license inspections and post-market supervision.
All five guidelines also took effect on November 1, 2026. The previous inspection guidance for these product categories was repealed at the same time.
Five Category-Specific Inspection Guidelines
The new documents translate the revised GMP and the applicable category-specific appendices into inspection items. They are intended for inspections of medical device registrants and contract manufacturers, while also providing companies with a basis for internal compliance reviews.
Sterile Medical Devices
The sterile medical device guideline applies to production inspections involving devices required to be supplied in a sterile condition.
Inspections will assess compliance against the revised medical device GMP and the corresponding sterile medical device requirements. Registrants and contract manufacturers should use the inspection items to review whether their quality systems, manufacturing controls and supporting records meet the updated framework.
Implantable Medical Devices
The implantable medical device guideline applies to the production inspection of devices intended to be implanted in the human body.
The revised inspection items align the category-specific requirements for implantable devices with the new GMP. Companies should check that their documented procedures and manufacturing records correspond to the activities and controls used for the registered products.
In Vitro Diagnostic Reagents
The IVD guideline provides the inspection basis for registrants and contract manufacturers producing in vitro diagnostic reagents.
It integrates the IVD-specific appendix with the revised GMP and establishes the inspection items used during manufacturing-license and post-market inspections. Companies supplying multiple IVD product lines should confirm that the applicable controls are implemented consistently across their production activities.
Custom-Made Dentures
The custom-made denture guideline applies to companies producing individually designed or manufactured denture products.
The document aligns inspections of these products with the revised GMP and the corresponding category-specific requirements. Manufacturers can use the inspection items to examine whether their procedures, production activities and records provide sufficient evidence of ongoing compliance.
Standalone Medical Software
The standalone software guideline applies to registrants and contract manufacturers of standalone medical software. Inspections involving software components incorporated into other medical devices may refer to the same guideline.
It contains 203 inspection items, divided according to their quality and safety risk:
- 41 critical items
- 94 major items
- 68 general items
The guideline introduces a more systematic inspection framework covering areas including software requirements management, design transfer, version release, lifecycle controls and cybersecurity.
For software companies, inspection readiness therefore extends beyond having general quality procedures. The relevant controls must be reflected in software-development activities, records and released product versions.
How Inspection Results Will Be Determined
Inspection types and the determination of results will follow the overarching Guidelines for Inspection of Good Manufacturing Practice in Medical Devices, issued by the NMPA in September 2026.
This creates a common inspection framework across the five product categories while retaining additional requirements relevant to each type of device.
The classification of inspection items as critical, major or general also allows companies to prioritize gaps according to their potential effect on product quality and safety. However, compliance reviews should cover the complete applicable checklist rather than focus only on critical items.
What the Revised Guidelines Mean for Foreign Companies
Foreign registrants and their Chinese agents should review which of the five inspection guidelines apply to their devices and examine the updated inspection-item lists.
The public and standardized criteria provide a clearer basis for conducting gap assessments before an inspection. They may also help companies coordinate QMS maintenance across different device categories using the common requirements of the revised GMP.
Standalone software companies face a particularly detailed checklist. Their review should address the complete software lifecycle, including requirements management, development controls, version release and cybersecurity.
Preparing for the New Inspection Framework
Companies affected by the revised guidelines should:
- Identify every category-specific guideline applicable to their products.
- Compare existing QMS procedures and records against the relevant inspection items.
- Review SOPs affected by the revised GMP and category-specific requirements.
- Assess software lifecycle, version-control and cybersecurity documentation where standalone software or software components are involved.
- Document identified gaps, corrective actions and staff training before an inspection.
Where several device categories are covered by the same quality system, companies should coordinate the review across product groups while retaining the controls and evidence required for each category.
Final Thoughts
The release of these five revised guidelines completes the category-specific inspection framework supporting China’s updated medical device GMP. As NMPA inspectors begin enforcing the new standards, manufacturers and foreign registrants must move beyond general quality assurance towards more detailed, category-specific compliance.
Meeting these requirements demands proactive gap analysis, robust documentation, and a clear understanding of both general and category-specific criteria. Cisema supports manufacturers in translating these regulatory requirements into practical compliance measures, from English translations and comparative gap analyses to registration impact assessments, QMS and SOP updates, and targeted regulatory training.
To ensure your operations are aligned with the NMPA framework, contact Cisema today.
Further Information
- Read about the general NMPA medical device GMP inspection guidelines.
- Review Cisema’s overview of the revised Good Manufacturing Practice for Medical Devices.
- Explore Cisema’s China medical device GMP compliance services.
References
- National Medical Products Administration, Notice on Issuing Four Guidelines for the Inspection of Good Manufacturing Practice for Sterile Medical Devices and Other Medical Device Categories, NMPA Medical Device Supervision [2026] No. 16.
- National Medical Products Administration, Notice on Issuing the Guidelines for the Inspection of Good Manufacturing Practice for Standalone Medical Software, NMPA Medical Device Supervision [2026] No. 17.
Connect with Cisema
With more than 20 years of experience and a team of over 100 specialists, Cisema helps global companies achieve compliance across Asia Pacific with confidence and accelerate market entry.
Stay Informed with Monthly News and Analysis
Stay informed with the latest regulatory changes, expert insights, and market opportunities across APAC, delivered straight to your inbox.


